Compare Cenovus Energy Inc (CVE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs TG Therapeutics Inc — how do they compare? Cenovus Energy Inc trades at $30.2 (market cap $55.00B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Cenovus Energy Inc is far larger — about 7.2× TG Therapeutics Inc's market cap, and Cenovus Energy Inc pays a 2.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CVE | TGTX | |
|---|---|---|
Market Cap | $55.00B | $7.64B |
Sector | Energy | Health |
52-Week High | $31.80 | $59.06 |
52-Week Low | $14.83 | $26.94 |
Enterprise Value | $61.08B | $7.84B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.14, up 1.96% with bullish technical signals and strong fundamentals. The stock shows robust earnings momentum with recent quarterly beats, supported by record oil sands production and disciplined cost management. Valuation metrics remain attractive with P/E of 11.56 and EV/EBITDA of 5.77, while profitability metrics include 11.48% net income margin and 20.96% ROE. Recent news highlights institutional buying interest and strong Q2 2026 operational performance.
CVE presents a compelling investment case with undervalued metrics and positive earnings trajectory, though exposure to volatile oil prices and refining margins poses risks. Analyst consensus leans bullish with 40.7% buy ratings, while technical indicators suggest continued upward momentum. The company's integrated model and growth projects support long-term value creation for shareholders.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
